ARDELYX INC
NASDAQ: ARDX (Ardelyx, Inc.)
Last update: 8 hours ago5.97
-0.02 (-0.33%)
| Previous Close | 5.99 |
| Open | 6.05 |
| Volume | 1,883,996 |
| Avg. Volume (3M) | 3,552,049 |
| Market Cap | 1,464,127,104 |
| Price / Earnings (Forward) | 33.11 |
| Price / Sales | 3.53 |
| Price / Book | 8.76 |
| 52 Weeks Range | |
| Earnings Date | 30 Apr 2026 |
| Profit Margin | -14.86% |
| Operating Margin (TTM) | -49.04% |
| Diluted EPS (TTM) | -0.230 |
| Quarterly Revenue Growth (YOY) | 61.00% |
| Total Debt/Equity (MRQ) | 124.68% |
| Current Ratio (MRQ) | 4.12 |
| Operating Cash Flow (TTM) | -47.54 M |
| Levered Free Cash Flow (TTM) | -17.22 M |
| Return on Assets (TTM) | -6.58% |
| Return on Equity (TTM) | -36.26% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Ardelyx, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 5.0 |
| Insider Activity | -1.5 |
| Price Volatility | -2.0 |
| Technical Moving Averages | 3.5 |
| Technical Oscillators | 1.5 |
| Average | 1.30 |
|
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. It product Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 2.51% |
| % Held by Institutions | 72.46% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Rock Springs Capital Management Lp | 31 Dec 2025 | 2,299,473 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 19.00 (Wedbush, 218.26%) | Buy |
| Median | 18.00 (201.51%) | |
| Low | 17.00 (BTIG, 184.76%) | Buy |
| Average | 18.00 (201.51%) | |
| Total | 3 Buy | |
| Avg. Price @ Call | 5.74 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Wedbush | 23 Feb 2026 | 19.00 (218.26%) | Buy | 5.75 |
| BTIG | 20 Feb 2026 | 17.00 (184.76%) | Buy | 5.73 |
| 29 Jan 2026 | 17.00 (184.76%) | Buy | 7.85 | |
| HC Wainwright & Co. | 20 Feb 2026 | 18.00 (201.51%) | Buy | 5.73 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| RAAB MICHAEL | - | 6.30 | -41,668 | -262,508 |
| Aggregate Net Quantity | -41,668 | |||
| Aggregate Net Value ($) | -262,508 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 6.30 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| RAAB MICHAEL | Officer | 15 Apr 2026 | Automatic sell (-) | 41,668 | 6.30 | 262,508 |
| RAAB MICHAEL | Officer | 15 Apr 2026 | Option execute | 20,834 | - | - |
| Date | Type | Details |
|---|---|---|
| 05 Feb 2026 | Announcement | Ardelyx to Report Full Year and Fourth Quarter 2025 Financial Results on February 19, 2026 |
| 03 Feb 2026 | Announcement | Ardelyx Receives New Patent for Tenapanor |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |